HUMACYTE INC

NASDAQ: HUMA (Humacyte, Inc.)

最近更新时间: 2天之前, 9:25PM

5.10

-0.08 (-1.54%)

  • 1天 -1.54%
  • 5天 -3.59%
  • 1月 5.59%
  • 6月 -10.05%
  • 今年至今天
  • 1年 83.45%
  • 5年 -47.26%
前收盘价格 5.18
收盘价格 5.13
成交量 3,189,547
平均成交量 (3个月) 4,740,867
市值 656,206,784
股市价格/股市净资产 (P/B) 30.28
52周波幅
2.48 (-51%) — 9.97 (95%)
利润日期 20 Mar 2025 - 24 Mar 2025
稀释每股收益 (EPS TTM) -1.34
总债务/股东权益 (D/E MRQ) 71.00%
流动比率 (MRQ) 1.10
营业现金流 (OCF TTM) -90.60 M
杠杆自由现金流 (LFCF TTM) -58.33 M
资产报酬率 (ROA TTM) -53.23%
股东权益报酬率 (ROE TTM) -850.81%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Humacyte, Inc. 看涨 看涨

AIStockmoo 评分

1.5
分析师共识 5.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 1.0
技术振荡指标 2.0
平均 1.50

相关股票

股票 市值 DY P/E（TTM） P/B
HUMA 656 M - - 30.28
CYTK 6 B - - 60.31
ARWR 2 B - - 13.19
FTRE 2 B - - 1.14
REPL 971 M - - 2.24
ABUS 648 M - - 5.83

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 26.87%
机构持股比例 30.02%

所有权

姓名 日期 持有股份
Monashee Investment Management Llc 30 Sep 2024 535,000
52周波幅
2.48 (-51%) — 9.97 (95%)
目标价格波幅
10.00 (96%) — 25.00 (390%)
高 25.00 (D. Boral Capital, 390.20%) 购买
25.00 (EF Hutton, 390.20%) 购买
中 16.00 (213.73%)
低 10.00 (TD Cowen, 96.08%) 购买
10.00 (BTIG, 96.08%) 购买
平均值 17.00 (233.33%)
总计 6 购买
平均价格@调整类型 4.90
公司 日期 目标价格 调整类型 价格@调整类型
Benchmark 23 Dec 2024 17.00 (233.33%) 购买 4.65
10 Oct 2024 15.00 (194.12%) 购买 5.55
D. Boral Capital 20 Dec 2024 25.00 (390.20%) 购买 4.64
21 Nov 2024 25.00 (390.20%) 购买 4.38
HC Wainwright & Co. 20 Dec 2024 15.00 (194.12%) 购买 4.64
18 Nov 2024 12.00 (135.29%) 购买 4.45
EF Hutton 28 Oct 2024 25.00 (390.20%) 购买 5.42
BTIG 18 Oct 2024 10.00 (96.08%) 购买 5.03
TD Cowen 18 Oct 2024 10.00 (96.08%) 购买 5.03

该时间范围内无数据。

  • 3M
日期 类型 细节
19 Dec 2024 公告 Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
02 Dec 2024 公告 Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
23 Nov 2024 公告 HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025
22 Nov 2024 公告 Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
22 Nov 2024 公告 HUMACYTE DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on January 17, 2025
21 Nov 2024 公告 Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
21 Nov 2024 公告 Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
21 Nov 2024 公告 HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
20 Nov 2024 公告 Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
19 Nov 2024 公告 Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
18 Nov 2024 公告 Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
14 Nov 2024 公告 Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
08 Nov 2024 公告 Humacyte Third Quarter 2024 Financial Results and Business Update
06 Nov 2024 公告 Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
28 Oct 2024 公告 Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
23 Oct 2024 公告 Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
22 Oct 2024 公告 Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
21 Oct 2024 公告 Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
19 Oct 2024 公告 Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
08 Oct 2024 公告 Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票